ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

FDA News: Tentative Approval Given IVAX Paxene; BMS Exclusivity Upheld

January 9, 1998

NCCS Networker Volume 5 Issue 4, Fall 1991

September 13, 1991

New Grant Program in Physical Activity

March 28, 2003

New Source of Research Funds? As Clinton Derails Tobacco Deal, Prospects May Brighten for Tougher Measures In ‘98

September 19, 1997

Senate Committee Approves $27 Billion for NIH, $4.6 Billion for NCI

August 2, 2002

“Forward Funding” Will Cost NCI $38 Million, 270 Grants, As OMB Legally Impounds FY 1985 Money

February 1, 1985